Western USA will be educated in the benefits of drug delivery system by new recruit Eliana Rivera
Early clinical phase drug developer Pharmaceutical Profiles is aiming to secure more projects from US pharmaceutical and biotechnology companies with the appointment of Eliana Rivera as director, business development, Team Enterion for the US western region.
Eliana, who will be based in the San Francisco Bay area, will be responsible for developing new projects with pharmaceutical and biotechnology companies and will focus on developing the demand for human drug absorption (HDA) study work, which uses the company's novel Enterion capsule drug delivery technology.
Pharmaceutical Profiles claims to be the world leader in the use of sophisticated medical imaging techniques to determine the in vivo performance and potential effectiveness of new drug formulations during the early stages of their development, helping pharmaceutical and biotechnology companies to focus solely on formulations with the greatest potential.
The development and introduction of the Enterion drug delivery capsule in 2000 enabled Pharmaceutical Profiles (by elucidating the complex oral biopharmaceutical properties of drugs in development) to help clients save time and money when developing new oral dosage forms.
The company has enjoyed consistent growth in business in North America, Europe and Japan since its inception in 1990.
Eliana brings more than 15 years of experience to her new role.
She began her career in medical diagnostics in 1987, working for Syntex for ten years and gaining experience and expertise in marketing, sales, product development and business development.
In 1997 she joined a small biotechnology company, developing marketing plans and hiring and training a sales team.
She then spent two years in Pennsylvania working on business development for IBAH, before a period working as a consultant to biotechnology and pharmaceutical companies. Commenting on her new appointment, she explained: "There is a hot bed of biotechnology and pharmaceutical companies throughout California and the Mid West and the most obvious challenge will be to educate them about the financial and time-saving benefits a company like Pharmaceutical Profiles can bring to their early phase drug development.
Eliana added, "I am excited about joining an organisation that offers a unique range of early phase development services and look forward to the challenge of promoting Pharmaceutical Profiles's capabilities."
